Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
Benzinga Newsdesk 4 months ago
News
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial targets the specific TNFR1
- PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED
- This FDA-aligned trial targets the specific TNFR1 genotype to maximize treatment effects, with ~70% of clinical sites already activated and patients in the run-in phase
- With only 13% of DED patients experiencing sustained relief, Licaminlimab has the potential to offer a targeted precision solution for a highly unsatisfied market